Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veru Inc. - Common Stock (NQ:VERU)

4.390 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veru Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
How Good Are Veru's Earnings? | Return On Capital Employed
According to Benzinga Pro data, during Q4, Veru (NASDAQ:VERU) posted sales of $15.65 million. Earnings were up 34.84%, but Veru still reported an overall loss of $1.87 million. In... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Veru Posts Mixed Q4 Results
Veru Inc (NASDAQ: VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million. FC2... 
Via Benzinga
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Veru: Q4 Earnings Insights
Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Veru... 
Via Benzinga
Veru: Q3 Earnings Insights
Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to... 
Via Benzinga
Earnings Outlook For Veru
On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And... 
Via Benzinga
Earnings Scheduled For December 2, 2021
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report earnings for its third quarter. • LightInTheBox Holding (NYSE:LITB) is... 
Via Benzinga
Earnings Outlook For Veru
Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
10 Consumer Staples Stocks Moving In Monday's After-Market Session
Gainers 111 (NASDAQ:YI) shares rose 3.81% to $4.35 during Monday's after-market session. The market value of their outstanding shares is at $360.4 million. The company's, Q3... 
Via Benzinga
Cramer Gives His Take On Change Healthcare, Veru And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Change Healthcare Inc. (NASDAQ: CHNG) is a good, steady firm. Cramer said with Veru Inc. (NASDAQ: VERU)... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Veru: Q2 Earnings Insights
Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.04),... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Why Veru Stock Vaulted Higher Today
An analyst raised his price target for the stock. 
Via The Motley Fool
Why Veru Stock Blasted Higher on Friday
An analyst argues that the company has far more value than many realize. 
Via The Motley Fool
Veru Stock Gains After Q3 Result Tops Estimates
Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2... 
Via Benzinga
Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients
Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent,... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Return On Capital Employed Overview: Veru
During Q2, Veru (NASDAQ:VERU) brought in sales totaling $13.34 million. However, earnings decreased 289.37%, resulting in a loss of $1.47 million. In Q1, Veru earned $777.00... 
Via Benzinga
Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19
Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients... 
Via Benzinga
Veru's FC2 Prescription Sales Boost Q2 Revenues
Veru Inc (NASDAQ: VERU) reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago. Sales... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Earnings Scheduled For May 12, 2021
Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter. • Boyd Gaming (NYSE:BYD) is projected to report... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.